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AbstrACt
Objectives Despite the publication of hundreds of 
trials on gout and hyperuricemia, management of these 
conditions remains suboptimal. We aimed to assess the 
quality and consistency of guidance documents for gout 
and hyperuricemia.
Design Systematic review and quality assessment using 
the appraisal of guidelines for research and evaluation 
(AGREE) II methodology.
Data sources PubMed and EMBASE (27 October 
2016), two Chinese academic databases, eight guideline 
databases, and Google and Google scholar (July 2017).
Eligibility criteria We included the latest version of 
international and national/regional clinical practice 
guidelines and consensus statements for diagnosis and/or 
treatment of hyperuricemia and gout, published in English 
or Chinese.
Data extraction and synthesis Two reviewers 
independently screened searched items and extracted 
data. Four reviewers independently scored documents 
using AGREE II. Recommendations from all documents 
were tabulated and visualised in a coloured grid.
results Twenty-four guidance documents (16 clinical 
practice guidelines and 8 consensus statements) published 
between 2003 and 2017 were included. Included documents 
performed well in the domains of scope and purpose (median 
85.4%, range 66.7%–100.0%) and clarity of presentation 
(median 79.2%, range 48.6%–98.6%), but unsatisfactory 
in applicability (median 10.9%, range 0.0%–66.7%) and 
editorial independence (median 28.1%, range 0.0%–83.3%). 
The 2017 British Society of Rheumatology guideline received 
the highest scores. Recommendations were concordant on 
the target serum uric acid level for long-term control, on 
some indications for urate-lowering therapy (ULT), and on 
the first-line drugs for ULT and for acute attack. Substantially 
inconsistent recommendations were provided for many 
items, especially for the timing of initiation of ULT and for 
treatment for asymptomatic hyperuricemia.
Conclusions Methodological quality needs improvement 
in guidance documents on gout and hyperuricemia. 
Evidence for certain clinical questions is lacking, despite 
numerous trials in this field. Promoting standard guidance 
development methods and synthesising high-quality 
clinical evidence are potential approaches to reduce 
recommendation inconsistencies.
PrOsPErO registration number CRD42016046104.
bACkgrOunD
Gout is an inflammatory arthritis occurring 
in response to monosodium urate (MSU) 
crystals formation, a common and necessary 
pathogenic factor of which is hyperuricemia. 
The prevalence of gout and hyperuricemia,1–4 
as well as their disease burden,5 6 are rising 
globally. However, although >600 related clin-
ical studies7 have been published to date, the 
quality of care for gout and hyperuricemia 
remains suboptimal. The goal of treatment is 
to reduce the body’s total uric acid pool8 9 and 
consequently to minimise the risk of acute 
flares, arthropathy, nephrolithiasis and other 
complications.7 10 11 A study in the USA found 
that only 22% of patients with gout received 
therapy adhering to all quality indicators.12 
A nationwide population study in the UK 
reported that only 48% of prevalent patients 
received proper consultation and only 27% 
strengths and limitations of this study
 ► The first systematic review to assess the quality of 
clinical practice guidelines and consensus state-
ments on the diagnosis and treatment for both hy-
peruricemia and gout.
 ► The first systematic review to summarise recom-
mendations for best practice in hyperuricemia and 
gout.
 ► The appraisal of guidelines for research and eval-
uation II instrument is an international, structured, 
validated and rigorously developed tool.
 ► Only guidance documents in English and Chinese 
were included.
 ► Literature search was >1 year old at the time of 
publication.
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of incident patients were provided with urate-lowering 
therapy (ULT) within 1 year of diagnosis.6
High-quality guidance documents are important for 
improving the quality of care for gout and hyperuricemia 
at individual, community and national levels.13 Current 
guidance documents for gout and hyperuricemia have 
been developed by rheumatology, endocrinology and cardi-
ology groups, at regional, national or international levels. 
Among these documents, the American College of Rheu-
matology (ACR) guidelines,14 15 updated in 2012, and the 
European League Against Rheumatism (EULAR) guide-
lines,16–18 updated in 2016, have the most substantial global 
influence. Besides, the most recent documents (released 
in 2017) are two national guidelines, from the American 
College of Physicians (ACP)19 20 and the British Society for 
Rheumatology (BSR),21 respectively, and one consensus 
statement, from the Chinese Multidisciplinary Expert Task 
Force on Hyperuricemia and Its Related Diseases.22
Despite the variety of documents, current guidelines and 
consensuses on gout and hyperuricemia provide incon-
sistent recommendations, even those released by highly 
respected professional organisations, such as the ACP and 
the ACR.23 Some distinct differences lie in key aspects for 
patient care, such as the pharmacological treatment for 
asymptomatic hyperuricemic patients, the timing of initi-
ation of ULT in patients with gout flare24 and indications 
for ULT.25 These discrepancies may result from ethnic and 
social differences, but can be a consequence of inconsis-
tent guideline development.23 Low-quality guidance docu-
ments put individual patients and communities at risk, and 
impede the application of guideline recommendations 
in clinical practice.26 Hence, we conducted this study to 
systematically evaluate the quality of clinical practice guide-
lines and consensus statements on gout and hyperuricemia 
and to compare key recommendations on patient care 
from all included documents.
MEthODs
Detailed methods of the study have been published previ-
ously27 and this study was registered with PROSPERO.
Literature search and selection criteria
We systematically searched PubMed and EMBASE from 
inception to 27 October 2016 using a comprehensive 
search strategy (online supplementary tables 1 and 2) 
to identify guidelines and consensus recommendations 
pertaining to the diagnosis and treatment of gout and 
hyperuricemia. We searched two academic databases for 
Chinese publications (the Chinese Biomedical Literature 
Database and the Wanfang Data) and eight guideline 
databases from inception to 24 July 2017 using search 
strategies tailored to different databases (online supple-
mentary table 3). We also searched Google and Google 
scholar in July 2017 for potentially eligible guidelines and 
consensus recommendations that were not indexed in 
the aforementioned databases.
We included the latest versions of all international 
and national/regional clinical practice guidelines and 
consensus statements for the diagnosis and/or treat-
ment of gout and hyperuricemia, published in English 
or Chinese. Two reviewers (QL, XL) independently 
screened all searched documents. Reasons for exclusion 
were provided for documents excluded during the full-
text review (online supplementary table 4). Disagree-
ments were resolved through discussion with a third 
reviewer (SL).
Data extraction
We extracted the following data from each included docu-
ment: document characteristics (eg, year of publication, 
funding body and evidence base), recommendations for 
diagnosis and monitoring of gout and hyperuricemia, and 
recommendations for management. Data were extracted 
by one investigator (QL) and checked by another (XL).
Appraisal of guidance documents
All included documents were assessed by four reviewers 
(QL, XL, JW and HL) independently using the appraisal 
of guidelines for research and evaluation (AGREE) II 
instrument.28 AGREE II is an internationally developed 
and validated tool to evaluate the quality of clinical prac-
tice guidelines29–31 and consensus statements.32 33
All reviewers completed an online training tutorial34 
before the commencement of appraisal to ensure stan-
dardisation. We adapted detailed instructions for scoring 
from the AGREE II User’s Manual28 and provided objec-
tive scoring criteria for each item (online supplementary 
file 1). We selected four guidance documents for pilot 
scoring, during which we discussed and clarified our 
objective scoring criteria. When scoring for all included 
documents was completed, a meeting was held among 
reviewers and every item with scores differed more than 
one point was discussed. After the meeting, reviewers 
were given the opportunity to revise their scores or to 
keep the original scores. We recorded all original scores, 
revised scores and reasons for modifying scores for quality 
control purpose, and used the intraclass correlation coef-
ficient (ICC) to test inter-rater reliability. The ICC was 
calculated via IBM SPSS Statistics 22.0 and an ICC ≥0.7 
was considered acceptable.35
recommendation synthesis
We manually extracted recommendations on key clin-
ical questions from all included guidance documents 
and summarised them into four tables: (1) the diagnosis 
of gout and hyperuricemia, (2) the treatment of hyper-
uricemia, (3) the treatment of acute gout and (4) the 
treatment of tophi. Recommendations were extracted by 
one investigator (QL) and checked by another (XL). We 
further visualised these recommendations in a five-colour 
grid to illustrate inconsistencies. The most frequently 
recommended content was used as a reference. We used 
green to colour documents providing consistent recom-
mendations, red to colour those providing contrary 
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Figure 1 Flow diagram for literature search. AGREE, appraisal of guidelines for research and evaluation; CBM, Chinese 
Biomedical Literature Database; GAIN, Guidelines and Audit Implementation Network; GIN, Guidelines InternationalNetwork; 
NGC, National Guideline Clearinghouse; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; 
SIGN, Scottish Intercollegiate Guidelines Network; TRIP, Turning Research into Practice Database
recommendations and blue to colour those providing 
partially consistent recommendations. A partially consis-
tent recommendation was defined as a recommendation 
that included but not the same as the reference content. 
Where recommendations were not given or were not 
applicable, the cell was coloured in yellow and in grey, 
respectively.
Patient and public involvement
Patients or the public were not involved in the conceptu-
alisation or carrying out of this research.
rEsuLts
search results
Overall, we identified 5811 items across academic data-
bases, guideline databases, Google and Google Scholar. 
After applying the inclusion and exclusion criteria, 
24 guidance documents from 26 papers14–22 36–52 were 
included in the final appraisal and recommendation 
synthesis (figure 1). Studies excluded after full-text review 
and reasons for exclusion were provided as online supple-
mentary table 4.
Characteristics of included guidelines and consensus 
statements
Table 1 summarised characteristics of included guid-
ance documents, among which 16 were clinical practice 
guidelines14–21 38 41 44–46 48–52 and 8 were consensus state-
ments.22 36 37 39 40 42 43 47 16 national or regional organisa-
tions and three international groups (ie, the 3e (evidence, 
expertise, exchange) Initiative, the EULAR and the devel-
opment group for the treat-to-target (T2T) recommenda-
tions) published these documents between 2003 and 2017. 
Sixteen documents14–18 21 22 36–38 40 42 43 45 46 49 50 were issued 
by rheumatology organisations and seven16–18 36 39 42 43 
were developed by multinational development groups. 
Seventeen documents14–18 21 22 36 38–41 43–46 49 51 provided 
information on their guideline development group, 
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Figure 2 Standardised domain scores for each guidance document. 3e, evidence, expertise, exchange Initiative; 3e_AU_NZ, 
Australian and New Zealand 3e Initiative; 3e_PT, Portuguese 3e Initiative; ACP, American College of Physicians; ACR, American 
College of Rheumatology; AMM, Academy of Medicine of Malaysia; ASCR, American Society of Clinical Rheumatologists; 
BSR, British Society for Rheumatology; CCCP, Chinese College of Cardiovascular Physicians; CRA, Chinese Rheumatology 
Association; CRA_multi, Chinese Multidisciplinary Expert Task Force on Hyperuricemia and Its Related Diseases; CSE, 
Chinese Society of Endocrinology; EULAR, European League Against Rheumatism; FMOH, Federal Ministry of Health (Nigeria); 
JSGNAM, Japanese Society of Gout and Nucleic Acid Metabolism; MOH, Ministry of Health Malaysia; MSR, Malaysian Society 
of Rheumatology; NIAMS, National Institute of Arthritis and Musculoskeletal and Skin Diseases; NIH, National Institutes of 
Health; PRA, Philippine Rheumatology Association; SAMA, South African Medical Association; SER, Spanish Society of 
Rheumatology; SIR, Italian Society of Rheumatology; T2T, treat-to-target; TRA, Taiwan Rheumatology Association; UTAustin, 
University of Texas at Austin.
among which 1114–17 19–21 36 41–43 45 46 explicitly stated 
the involvement of a methodologist. Twelve docu-
ments14–18 21 22 38–41 43–46 49 51 provided information on their 
target audience, among which only three16 38 44 consid-
ered patients as one of the target audiences. Eighteen 
documents14–21 36 39–43 45 46 48–52 conducted systematic liter-
ature review as part of their development process, among 
which 17 documents14–21 36 39–41 43 45 46 48–52 reported the 
level of evidence supporting recommendations and 
1616–21 36 39–41 43 45 46 48–52 graded the strength of recommen-
dations. Ten documents16 19–21 39 42 46 48 49 51 52 clearly stated 
being externally reviewed. Five19–21 46 49 50 provided a clear 
time of update plan. Twelve documents14 15 17–21 36 39 42 46 49 51 52 
provided information on their funding body, among which 
six17 36 39 46 49 51 were fully or partially funded by the phar-
maceutical industry and the rest did not clearly declare 
their funding body.
Appraisal of guidelines and consensus statements
Standardised AGREE II domain scores for each guidance 
document were shown as figure 2 and were provided in 
value as online supplementary table 5. Scores for each 
AGREE II item were provided in mean as online supple-
mentary table 6 and in detail as online supplementary 
table 7. The overall quality of guidance documents, as 
assessed by AGREE II, varied both between documents 
across domains and within documents between domains. 
The document with the highest domain scores was the 
gout management guideline published by the BSR in 
2017,21 with five domains scoring above the upper quar-
tile, followed by the guidelines published by the ACP in 
2017,19 20 and the 2015 gout classification criteria by the 
ACR and the EULAR jointly,42 both with four domains 
scoring above the upper quartile. Guidelines did not 
always score higher than consensus statements. No 
tendency of improvement in the quality score over time 
was observed (online supplementary figure 1).
The AGREE II instrument evaluated guidelines and 
consensus statements in six domains, from the devel-
opment, dissemination to implementation. The scope 
and purpose (domain 1) of a document clarifies its 
clinical questions. Proper involvement of stakeholders 
(domain 2) balances individuals’ biases. The rigour of 
development domain (domain 3) is most concerned 
by clinicians and ensures the validity of development 
methodology.53 Clearly presented recommendations 
(domain 4) conveyed precise and accessible informa-
tion from the development group to clinicians. Good 
performances in the applicability domain (domain 
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5) and the editorial independence domain (domain 
6) guarantee the usefulness and the independence of 
documents.
Guidance documents received the highest scores for 
the scope and purpose domain (median 85.4%, range 
66.7%–100.0%) and the clarity of presentation domain 
(median 79.2%, range 48.6%–98.6%), and the lowest 
scores for the applicability domain (median 10.9%, range 
0.0%–66.7%) and the editorial independence domain 
(median 28.1%, range 0.0%–83.3%). The worst scored 
item was the monitoring or auditing criteria item (mean 
score 1.2, range 1.0–4.0), followed by the implementa-
tion advice or tools item (mean 1.7, range 1.0–4.8), the 
external review item (mean 2.1, range 1.0–6.0) and the 
updating procedure item (mean 2.1, range 1.0–6.5).
The ICC was 0.896. Group discussion modified 
365/2208 (16.53%) of individual scores.
synthesis of recommendations
Included guidance documents addressed four major 
themes: diagnosis of gout and hyperuricemia, treatment 
for hyperuricemia, treatment for acute gout attack and 
treatment for tophi. Figure 3 showed key recommenda-
tions and their inconsistencies.
Approaches to diagnostic strategies for gout and 
hyperuricemia
Thirteen guidance documents17–20 22 36 38 40–43 46 49 51 
covered the diagnosis of gout and 1117 22 37 38 45–51 covered 
that of hyperuricemia. Online supplementary table 8 
showed key recommendations. The identification of 
MSU crystals in synovial fluid or tophi was a gold standard 
for definite diagnosis, as recommended by all included 
documents. In the absence of MSU crystals, three aspects 
were commonly evaluated for gout diagnosis, namely the 
clinical manifestation, considered by all documents; the 
laboratory result, considered by all but one document49; 
and the imaging result, considered by all but four docu-
ments.17 19 20 49 51
Guidance documents differed when recommending the 
cut-off serum uric acid (SUA) level to diagnose hyperuri-
cemia. For the patient population in general, four docu-
ments38 47 48 51 recommended 7.0 mg/dL (or 420 μmol/L) 
as the cut-off, while two17 45 preferred 6.8 mg/dL. Five 
documents22 37 46 49 50 provided gender-specific cut-offs, 
recommending 6.0 mg/dL (or ~360 μmol/L) in female 
and 7.0 mg/dL (or ~420 μmol/L) in male. Asymptomatic 
hyperuricemia was defined in seven documents,36 38 46–50 
among which six36 38 46–48 50 excluded patients with gout 
and two36 48 excluded patients with tophi when making 
the diagnosis. Attitudes were inconsistent for whether or 
not patients with renal diseases can be diagnosed with 
asymptomatic hyperuricemia. Patients with renal diseases 
were not eligible for the diagnosis in the Japanese48 and 
the Philippine50 guidelines, but patients with pre-existing 
renal or cardiovascular diseases can receive this diagnosis 
in the 3 Initiative document.36
Approaches to treatment for hyperuricemia
Twenty-two guidance documents14–17 19–22 36–41 43–52 
covered the treatment for hyperuricemia and online 
supplementary table 9 summarised key recommenda-
tions. All but three documents19 20 44 52 explicitly provided 
target levels for long-term SUA control, most of which 
recommended 6.0 mg/dL (or 360 μmol/L), except the 
South African guideline51 which recommended 5.0 mg/
dL (300 μmol/L). Two documents16 22 recommended a 
lower limit of 3.0 mg/dL (or 180 μmol/L) for long-term 
SUA management. Among these two documents, only 
the 2016 EULAR guideline16 explained the reason for 
providing a lower limit was that low SUA might increase 
the risk of neurodegenerative diseases, but the level of 
evidence and the grade of recommendation were both 
low.
All but six guidance documents36 39 40 43 44 52 provided 
explicitly indications for long-term ULT. The most 
commonly recommended indications were recurrent 
attacks,14–17 19–22 41 45 48–51 tophi,14–17 19–22 38 41 45 48–51 urate 
nephrolithiasis,14–17 19–22 37 38 49 50 arthropathy16 17 21 22 38 41 45 49 
and comorbidities.14–16 19–22 37 47 49 50 The definition of recur-
rent attacks varied from at least once per year17 to at 
least three times per year,49 while the majority of docu-
ments14–16 19–21 41 recommended twice per year as the 
cut-off.
Regarding the timing to initiate ULT, the documents 
did not agree on whether to start pharmacological ULT 
after an acute attack17 21 22 36–38 40 48 49 51 52 or during an 
attack.14 15 37 When recommending to start ULT after an 
attack, the preferred time to wait since the attack resolved 
varied from 2 weeks37 48 to 6 weeks.52 All guidance docu-
ments based their recommendation for this question 
on expert opinions, due to insufficient evidence. The 
explanations provided for starting ULT after an attack 
were that ULT was better discussed when a patient was 
not painful,21 and that ULT initiation could prolong or 
worsen the acute attack.51 Two documents16 39 explicitly 
presented the currently conflicting views and insufficient 
evidence and stated consequently no recommendation 
for this issue.
When pharmacological ULT options were explicitly 
provided, allopurinol was recommended by all guid-
ance documents14–17 21 36 40 43 45 46 48–50 to be the first-
line drug, while febuxostat was recommended by three 
documents14 15 17 46 to be the first-line and by six docu-
ments16 21 36 40 43 45 to be the second-line. However, recom-
mendations on the dosage of allopurinol varied largely. 
The maximum daily allopurinol dose recommended 
varied from 300 mg,51 600 mg,22 37 47 800 mg,14 15 17 38 45 to 
900 mg,21 43 46 and the daily starting dose recommended 
in patients with normal renal function varied from 
50 mg19 20 22 47 48 51 to 200 mg.21 As for patients with impaired 
renal function, the cut-off renal function to initiate dose 
adjustment was provided diversely as creatinine clearance 
20–140 mL/min,37 45 46 49 51 or estimated glomerular filtra-
tion rate (eGFR) 130 mL/min/1.73 m2.21 One document 
preferred to depend allopurinol dosage solely on eGFR 
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Figure 3 Summary of key recommendations for the diagnosis and treatment of gout and hyperuricemia. 3e, evidence, 
expertise, exchange Initiative; 3e_AU_NZ, Australian and New Zealand 3e Initiative; 3e_PT, Portuguese 3e Initiative; ACP, 
American College of Physicians; ACR, American College of Rheumatology; AMM, Academy of Medicine of Malaysia; 
ASCR, American Society of Clinical Rheumatologists; BSR, British Society for Rheumatology; CCCP, Chinese College of 
Cardiovascular Physicians; CRA, Chinese Rheumatology Association; CRA_multi, Chinese Multidisciplinary Expert Task 
Force on Hyperuricemia and Its Related Diseases; CSE, Chinese Society of Endocrinology; EULAR, European League 
AgainstRheumatism; FMOH, Federal Ministry of Health (Nigeria); JSGNAM, Japanese Society of Gout and Nucleic Acid 
Metabolism; MOH, Ministry of Health Malaysia; MSR, Malaysian Society of Rheumatology; NIAMS, National Institute of Arthritis 
and Musculoskeletal and Skin Diseases; NIH, National Institutes of Health; PRA, Philippine Rheumatology Association; SAMA, 
South African Medical Association; SER, Spanish Society of Rheumatology; SIR, Italian Society of Rheumatology; T2T, treat-to-
target; TRA, Taiwan Rheumatology Association; UTAustin, University of Texas at Austin.
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by limiting the maximum daily dose to 1.5 mg/eGFR 
in patients with renal impairment.22 HLA-B*5801 gene 
screening prior to allopurinol use was recommended by 
five guidance documents.14 15 21 22 37 38
For patients with asymptomatic hyperuricemia, 14 
guidance documents14 15 17 21 36–40 43 47–49 51 52 commented 
on the option of pharmacological ULT, among which, 
517 21 38 51 52 explicitly recommended no treatment under 
any circumstances. Three documents47–49 recommended 
pharmacological treatments in asymptomatic hyperuri-
cemia patients with comorbidities47 48 or with very high 
SUA levels,40 47–49 but their cut-off SUA level to indicate 
ULT varied from 8.0 mg/dL47 48 to 13.0 mg/dL.49 We also 
found that the Portuguese consensus40 was incoherent 
itself by stating that no pharmacological ULT was recom-
mended as a general principle, but also stating that phar-
macological ULT was recommended for patients with SUA 
higher than 9 mg/dL. No direct evidence was provided 
by any document to support pharmacological treatment 
for asymptomatic hyperuricemia, and such recommenda-
tions were only made in concern of the onset of gout40 
and the risk of cardiovascular events.47 48
Approaches to treatment for acute gout attack
Twenty-one guidance documents14–17 19–22 36–41 43–46 48–52 
covered the treatment for acute gout attack and online 
supplementary table 10 summarised their key recommen-
dations. Non-steroidal anti-inflammatory drugs (NSAIDs) 
was recommended by all but three documents19 20 39 44 as 
the first-line pharmacological treatment, while colchi-
cine by 11 documents.14–17 21 22 36 37 40 43 45 48 Colchicine 
was recommended to be given in a fixed dose by three 
documents38 40 48 and in a loading dose followed by 
different doses by six documents.14–17 19 20 22 38 51 52 Seven 
documents21 36 41 43 45 49 50 only recommended the total 
daily dose for colchicine, regardless of the regimen, 
and their doses recommended varied from 1 mg21 49 50 
to 2.4 mg.49 Suprisingly, one document43 recommended 
1.8 g colchicine in 24 hours without any further expla-
nation, which was likely a typo. Systemic steroids were 
recommended by all but 3 documents,37 39 44 among 
which 614–17 19 20 36 43 recommended them as the first-line 
option and 1021 22 38 41 45 46 48 50–52 recommended them 
when NSAIDs and colchicine were contraindicated or 
intolerant. Intra-articular steroids injection was recom-
mended by 14 documents,14–17 21 22 36 38 40 43 45 46 49 51 52 
among which 514–16 21 36 43 clearly recommended it as the 
first-line option.
Approaches to treatment for tophi
Twenty-one guidance documents14–17 19–22 36–41 43–46 48–52 
covered treatment for tophi and online supplementary 
table 11 showed their key recommendations. Surgery was 
recommended by nine documents,22 36 38 40 43 48 49 51 among 
which five22 36 38 43 49 explicitly presented its indications, 
most commonly nerve compression22 36 38 43 and infec-
tion.36 38 43 The risk for surgery was only discussed by one 
document51 and only the risk of delayed wound healing 
was stated. Long-term ULT was recommended by all but 
two documents,44 52 but the drugs used for pharmacolog-
ical treatment was only explicitly recommended by eight 
of them.15–17 21 37 43 46 51
DisCussiOn
Principal findings and interpretations
This systematic review, including 16 guidelines and 8 
consensus statements, found generally low methodolog-
ical quality and inconsistent recommendations from 
guidance documents covering the diagnosis and manage-
ment of gout and hyperuricemia. During revision of our 
work, the English version of two documents, from the 
Chinese Multidisciplinary Expert Task Force on Hyper-
uricemia and Related Diseases54 and the Taiwan Rheuma-
tologist Association,55 respectively, were released. Despite 
increase in the number of guidance documents published 
between 2003 and 2017, the quality of documents in all 
domains did not seem to improve with time. To date, this 
is the first systematic appraisal for the quality of guide-
lines and consensus statements pertaining to both gout 
and hyperuricemia.
Comparison with existing research
Guidance documents assessed in our study performed 
well in the domains of scope and purpose (domain 1) 
and clarity of presentation (domain 4), but poorly in the 
domain of applicability (domain 5). These results were 
consistent with two previous reviews,56 57 one of which 
systematically assessed the quality of all guidelines for 
gout and the other assessed three documents released, 
respectively, by the 3e Initiative,36 the ACR14 15 and the 
EULAR.18 58 Our study systematically included both 
guidelines and consensus statements in the field of both 
gout and hyperuricemia, and the diverse performance by 
different AGREE II domains was shared across both types 
of document.
This distribution of AGREE II domain scores has been 
observed by many previous guideline appraisal studies, in 
which documents scored higher in the scope and purpose 
domain and the clarity of presentation domain, and lower 
in the applicability domain and the editorial independence 
domain. This domain score distribution was not only shared 
by guidance documents for endocrinology diseases, such as 
diabetes59 60 and thyroid disorders,31 61 and rheumatology 
diseases, such as rheumatoid arthritis32 62 63 and systemic 
lupus erythematosus,64 but also shared by documents for 
diseases in other clinical specialities.33 65–67 Despite gener-
ally low and varied scores in the applicability domain, guid-
ance documents for gout and hyperuricemia performed 
obviously poorer comparing with documents for other 
conditions,31–33 59–61 63–67 suggesting that improving the 
usefulness of guidance being more challenging in gout and 
hyperuricemia. One major impediment to good applica-
bility of guidance document is the time and cost to perform 
economic evaluations and pilot studies, and a stable and 
long-term task force of guideline development is required 
copyright.
 o
n
 August 27, 2019 at UCL Library Services. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026677 on 24 August 2019. Downloaded from 
10 Li Q, et al. BMJ Open 2019;9:e026677. doi:10.1136/bmjopen-2018-026677
Open access 
to conduct these evaluations and studies. Although forming 
such a task force is practically difficult in some regions and 
countries, guidance documents were suggested to at least 
inform audience the need to consider these issues.65 Low 
scores in the editorial independence domain often resulted 
from lacking of detailed information on the influence of 
funding body and on the conflict of interests. We found 
that 50% of documents declaring funding sources were 
supported by the pharmaceutical industry, calling for aware-
ness of the potential influence of pharmaceutical industry 
on the synthesis of clinical guidance and for the need of 
promoting transparency in financial declaration.
Clinical implications and future research
Guidance documents were concordant and recom-
mended a target for SUA <6.0 mg/dL (or 360 μmol/L) 
for long-term control, to consider recurrent attacks as 
one of the indications for ULT (although the definitions 
for recurrent attacks differed), to consider allopurinol 
as the first-line ULT and NSAIDs as the first-line drug in 
acute attack, and to consider long-term ULT in patient 
with tophi. Despite these similarities, recommendations 
differed in the majority of items and these discrepancies 
might come from several sources, including ethnic differ-
ence, quality of documents and lack of evidence.
Ethnical and social differences are important reasons 
why recommendations may vary between guidelines and 
consensus, and such diversity is to be encouraged, in order to 
best meet the needs of local populations. One example was 
that Asian guidance documents were more likely to recom-
mend HLA-B*5801 gene screening before prescribing allo-
purinol.22 37 38 HLA-B*5801 gene screening was promoted 
because the risk of hypersensitivity reactions associated with 
allopurinol is significantly increased in individuals carrying 
the variant allele HLA-B*5801. Studies suggested that the 
frequency of this variant allele are higher in Han Chinese, 
Korean and Tai people than that in the Caucasian popula-
tion,14 15 21 and that that HLA-B*5801 gene screening prior 
to allopurinol initiation is cost-effective for Asians but not 
Caucasians.68 69 These findings are consistent with the pref-
erences of Asian documents. Providing ethnicity-specific 
recommendations or explicitly specifying the ethnicity of 
target audience helps clarify this source of inconsistency 
and improves the precision of recommendations.
However, it is worrying that low methodological quality 
of guidance documents may also lead to discrepant recom-
mendations and consequent variability in application. 
Our study suggested that comparing to high-quality docu-
ments,16 19–21 36 42 46 low-quality ones22 37 38 44 47 52 were more 
likely to provide ambiguous prioritisation of both (1) ULT 
drugs for hyperuricemia and (2) steroid options for acute 
attack. A quick notice was that when making this rough 
summary, we considered a document to be high-quality 
when it scored above the upper quartile in at least three 
out of the six AGREE II domains, and to be low-quality 
when it scored below the lower quartile in at least three 
out of the six AGREE II domains. Among all AGREE II 
domains, those pertaining to stakeholder involvement, 
rigour of development, applicability and editorial inde-
pendence could be improved by standardising developing 
processes, which consequently improved the reliability of 
recommendations. These results reinforced that it is better 
for clinicians to refer to high-quality guidance documents 
instead of the low-quality ones. However, when high-quality 
documents are unavailable in local language, referring to 
low-quality local documents might mislead clinical practice 
in the region. Selecting appropriate guidance documents 
to follow in clinical practice is thus more challenging for 
non-English speaking countries, including China.13 More-
over, the oldest document included in our study was the 
South African Medical Association guideline, published 
in 2003, and no guidance document in either English or 
Chinese was released in South African in the last 16 years. 
This finding suggested that some old documents might still 
affect regional practice. Efforts to timely update or declare 
the withdrawal of existing guidance documents are also crit-
ical for clinical practice.
Guidance documents are considered as the starting 
point to identify evidence gaps and to prioritise 
research questions.70 Evidence gaps were discussed in 
the recommendations of both (1) treatment for asymp-
tomatic hyperuricemia, by 514 15 36 37 39 43 out of 14 docu-
ments,14 15 17 21 36–40 43 47–49 51 52 and (2) timing to initiate 
ULT, by 216 39 out of 14 documents.14–17 21 22 36–40 48 49 51 52 
Although the rest of documents provided explicit recom-
mendations, they based their recommendations either 
on indirect evidence or expert opinions. As for gout and 
hyperuricemia, evidence synthesis is warranted for the 
effects of pharmacological ULT in patients with asymp-
tomatic hyperuricemia and for the optimal timing to 
initiate ULT in patients with the acute attack.
strengths and limitations
Strengths of our review included a systematic approach 
to identify guidance documents pertaining to the diag-
nosis and management of hyperuricemia and gout. Both 
guidelines and consensus statements were evaluated and 
compared. We used the AGREE II instrument, an interna-
tional, validated and rigorously developed tool, to assess 
the quality of document development and we tailored the 
AGREE II instrument to point-by-point scoring criteria 
(online supplementary file 1) to improve the objectivity 
and reproducibility of our study. We summarised all key 
recommendations, and compared and visualised the 
inconsistencies among them, providing a concise but 
informative overview for clinicians and researchers.
Our study also has limitations. First, we only included 
documents published in English or Chinese, which could 
lead to a risk of neglecting essential documents from 
regions not using English or Chinese as the first language. 
We attempted to mitigate this risk by tailoring our search 
strategy to identify the English versions of guidance docu-
ments published from these regions. Second, unconscious 
bias from a subjective rating of documents was inevitable. 
We avoided inviting coauthors of guidance documents 
as reviewers to prevent subconscious competing interest, 
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and conducted two rounds of group discussions to mini-
mise subjective bias. Third, the AGREE II instrument 
itself has weaknesses,31 59 67 71 although it was the most 
commonly used tool to assess the quality of guidance 
documents. The AGREE system assigned equal weight to 
all six domains, regardless of their relative importance.72 
Although better methods of guideline development and 
greater transparency of reporting are associated with more 
reliable recommendations, they do not guarantee better 
patient outcomes. Hence, the quality scores assessed by 
the AGREE II should be interpreted with caution, espe-
cially when used to indicate which guidelines to follow in 
clinical practice. Moreover, the subjective interpretation 
of scoring criteria impeded the replicability of AGREE II 
studies and direct comparison of quality scores in guid-
ance documents provided by different reviews. Fourth, 
our literature search was over 12 months old when the 
study was ready to publish, affecting the timeliness of our 
study. However, we eventually decided not to update the 
literature at a late stage of the study, because of the infea-
sibility of bringing together all reviewers with another 
round of centralised training and appraisal, and the risk 
of inconsistent scoring criteria for each reviewer after a 
long time since their previous scoring. Moreover, a quick 
review of publications in PubMed, using the same search 
strategy (online supplementary table 1) and limiting the 
publication date from 1 September 2016 to 21 January 
2019, did not found any new relevant documents, reas-
suring us of the timeliness of our study.
COnCLusiOns
The methodological quality needs to be improved in the 
current guidelines and consensuses on the diagnosis and 
management of gout and hyperuricemia, as assessed by the 
AGREE II. Inconsistent recommendations are common, 
even in some key aspects. Promoting standard methods 
for guidance documents development, and synthesising 
high-quality clinical evidence to fill in evidence gaps, are 
warranted to improve the quality of guidance documents.
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